Quantcast

Industry news that matters to you.  Learn more

Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development

Reading time: 1 – 2 minutes

Agendia recently announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

“This exciting early stage research collaboration represents a potential new area for additional commercialization and expansion of Agendia’s platform technology,” said David Macdonald, Agendia’s President and CEO. “We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo.”

Macdonald noted that Agendia has a long history of providing clinically valuable information about gene expression in oncology. “With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research,” he said.

As part of the agreement between Agendia and Daiichi Sankyo, Agendia technology will be used to assess patient samples. Terms and other aspects of the agreement were not disclosed.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

Source: Agendia